Yaron Carmi’s research featured in the New York Times

Department of Pathology

20 October 2022
Yaron Carmi’s research featured in the New York Times



Co-authored with 

·  Amit Gutwillig

·  Nadine Santana-Magal

·  Leen Farhat-Younis

·  Diana Rasoulouniriana

·  Asaf Madi

·  Chen Luxenburg

·  Jonathan Cohen

·  Krishnanand Padmanabhan

·  Noam Shomron

·  Guy Shapira

·  Annette Gleiberman

·  Roma Parikh

·  Carmit Levy

·  Meora Feinmesser

·  Dov Hershkovitz

·  Valentina Zemser-Werner

·  Oran Zlotnik

·  Sanne Kroon

·  Wolf-Dietrich Hardt

·  Reno Debets

·  Nathan Edward Reticker-Flynn

·  Peleg Rider

·  Madi, Luxenburg, Shomron, and Levy are co-Preclinical Faculty members at the Faculty of Medicine. 


Yaron Carmi’s research describes a mechanism that may help overcome the challenges with immunotherapy for cancer. 


Dr. Yaron Carmi at the Department of Pathology completed his PhD studies summa cum laude at Ben-Gurion University of the Negev and won the Pratt award for excellence PhD students. He completed his postdoctoral training at the Department of Immunology at Stanford University, where he earned the Young Investigator Award. His work on dendritic cell vaccination was published in Nature and Cell and he has co-authored manuscripts in peer-reviewed journals, including Science and Immunity, and written four patents. Based on his findings, he co-founded two companies, Bolt Therapeutics and more recently, Gilboa Therapeutics, and he serves as a consultant in Velocity Pharmaceutical Development venture capital, and as a board member at the Israel Society for Gene and Cell Therapy. Carmi was awarded the Alon Fellowship for outstanding young Israeli scientists.




The research was published in eLife on Sept 20, 2022




Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>